Syndax Pharmaceuticals Q3 operating expenses $125.193 million
SNDX•Syndax Pharmaceuticals reported third-quarter net income of negative $49.433 million, compared with an IBES estimate of negative $45.2 million, and operating income of negative $41.895 million.
1. Quarterly results
Syndax Pharmaceuticals reported third-quarter net income of negative $49.433 million, versus an IBES estimate of negative $45.2 million. Operating income was negative $41.895 million.
